ANDA 71910, held by Curium. Sodium Iodide I-123.
As of Nov 16, 2026, ANDA 71910 (Sodium Iodide I 123), held by Curium, was first approved by FDA on Feb 28, 1989, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Administration of Sodium Iodide I 123 Capsules is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 1989 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Iodide I 123200uCi ยท capsule;oral | Sodium Iodide I-123 | Rx |
| Jun 29, 1993 | Supplement 3Manufacturing | Approved | None posted |
| Mar 18, 1991 | Supplement 1Manufacturing | Approved | None posted |
| Mar 18, 1991 | Supplement 2Manufacturing | Approved | None posted |
| Feb 28, 1989 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters